- Conditions
- Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 260
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Macular Degeneration
- Interventions
- abicipar pegol, ranibizumab, sham procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age Related Macular Degeneration, Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Aflibercept, Triamcinolone Acetonide, Verteporfin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- aflibercept 8 mg PFS
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • The Woodlands, Texas
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- episcleral brachytherapy
- Radiation
- Lead sponsor
- Salutaris Medical Devices, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- ‘Aiea, Hawaii • Oak Forest, Illinois
- Conditions
- Age-Related Macular Degeneration
- Interventions
- KH631
- Drug
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SF0166 Topical Ophthalmic Solution
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Physician-guided diagnostic
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
- Conditions
- Geographic Atrophy of the Macula
- Interventions
- GAL-101, Placebo
- Drug
- Lead sponsor
- Galimedix Therapeutics Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept (2.0 mg)
- Biological
- Lead sponsor
- Exegenesis Bio
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Reno, Nevada • Erie, Pennsylvania
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Age-related Macular Degeneration
- Interventions
- Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- OTX-TKI
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Santa Barbara, California • Waterford, Connecticut + 4 more
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
- Interventions
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
- Conditions
- Macular Degeneration
- Interventions
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
- Drug · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 2.0 aflibercept, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 998 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- Subretinally injected RetinoStat
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
- Conditions
- Neovascular (Wet) AMD
- Interventions
- ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
- Drug
- Lead sponsor
- Avirmax Biopharma Inc
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Dorzolamide-timolol
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age - Related Macular Degeneration (AMD)
- Interventions
- Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon